دورية أكاديمية

MRI radiomics to monitor therapeutic outcome of sorafenib plus IHA transcatheter NK cell combination therapy in hepatocellular carcinoma.

التفاصيل البيبلوغرافية
العنوان: MRI radiomics to monitor therapeutic outcome of sorafenib plus IHA transcatheter NK cell combination therapy in hepatocellular carcinoma.
المؤلفون: Yu, Guangbo, Zhang, Zigeng, Eresen, Aydin, Hou, Qiaoming, Garcia, Emilie Elizabeth, Yu, Zeyang, Abi-Jaoudeh, Nadine, Yaghmai, Vahid, Zhang, Zhuoli
المصدر: J Transl Med ; ISSN:1479-5876 ; Volume:22 ; Issue:1
بيانات النشر: BioMed Central
سنة النشر: 2024
المجموعة: PubMed Central (PMC)
مصطلحات موضوعية: Hepatocellular carcinoma (HCC), Immunotherapy, Magnetic resonance imaging (MRI), Natural killer cell, Radiomics, Sorafenib
الوصف: Hepatocellular carcinoma (HCC) is a common liver malignancy with limited treatment options. Previous studies expressed the potential synergy of sorafenib and NK cell immunotherapy as a promising approach against HCC. MRI is commonly used to assess response of HCC to therapy. However, traditional MRI-based metrics for treatment efficacy are inadequate for capturing complex changes in the tumor microenvironment, especially with immunotherapy. In this study, we investigated potent MRI radiomics analysis to non-invasively assess early responses to combined sorafenib and NK cell therapy in a HCC rat model, aiming to predict multiple treatment outcomes and optimize HCC treatment evaluations.
نوع الوثيقة: article in journal/newspaper
اللغة: English
العلاقة: https://doi.org/10.1186/s12967-024-04873-wTest; https://pubmed.ncbi.nlm.nih.gov/38243292Test; https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10797785Test/
DOI: 10.1186/s12967-024-04873-w
الإتاحة: https://doi.org/10.1186/s12967-024-04873-wTest
https://pubmed.ncbi.nlm.nih.gov/38243292Test
https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10797785Test/
حقوق: © 2024. The Author(s).
رقم الانضمام: edsbas.6AC482AE
قاعدة البيانات: BASE